Related references
Note: Only part of the references are listed.Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects
Yanli Wang et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2023)
Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling
Ming Chang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)
Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis
Peiyan Zheng et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2022)
Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
Melanie McPhail et al.
FRONTIERS IN MEDICINE (2022)
Rapid Analytical Method Development and Validation for the Simultaneous Estimation of 5-Fluorouracil and Cannabidiol in Plasma and Lipid-based Nanoformulations
Nazeer Hasan et al.
CURRENT ANALYTICAL CHEMISTRY (2022)
Cannabis as a potential compound against various malignancies, legal aspects, advancement by exploiting nanotechnology and clinical trials
Nazeer Hasan et al.
JOURNAL OF DRUG TARGETING (2022)
Recent update on electrospinning and electrospun nanofibers: current trends and their applications
Arif Nadaf et al.
RSC ADVANCES (2022)
Docetaxel-dasatinib combination: A strategy to overcome unfavorable treatment outcomes due to dose reduction
Grace Lovia Allotey-Babington et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2021)
FORMULATION, OPTIMIZATION, AND IN VITRO CHARACTERIZATION OF DASATINIB LOADED POLYMERIC NANOCARRIERS TO EXTEND THE RELEASE OF THE MODEL DRUG
SANDEEP KUMAR REDDY ADENA et al.
International Journal of Applied Pharmaceutics (2021)
Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose
Nazeer Hasan et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2021)
β-Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation
Paola Mantuano et al.
BIOMOLECULES (2021)
Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
Zakaria Maat et al.
CASE REPORTS IN ONCOLOGY (2021)
A small molecule nanodrug consisting of pH-sensitive ortho ester-dasatinib conjugate for cancer therapy
Jialu Gao et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2021)
Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
Eleonora Russo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Carrier-free prodrug nanoparticles based on dasatinib and cisplatin for efficient antitumor in vivo
Lu Yang et al.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer
Fatemah Bahman et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Dasatinib-A Generation Ahead
Subramaniam Murali Carthikeyan et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2021)
Dasatinib loaded nanostructured lipid carriers for effective treatment of corneal neovascularization
Qingqing Li et al.
BIOMATERIALS SCIENCE (2021)
A rare case of late presentation of dasatinib-induced cardiopulmonary toxicity
Harshit Khurana et al.
INDIAN JOURNAL OF RESPIRATORY CARE (2021)
Dasatinib protects humanized mice from acute HIV-1 infection
Maria Salgado et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Dasatinib, a second-generation tyrosine kinase inhibitor, induces melanogenesis via ERK-CREB-MITF-tyrosinase signaling in normal human melanocytes
Bogyeong Kang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Micelles entrapped microparticles technology: a novel approach to resolve dissolution and bioavailability problems of poorly water soluble drugs
Durga Maheswari Parvataneni et al.
JOURNAL OF MICROENCAPSULATION (2020)
Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib
Raquel Carvalho Montenegro et al.
Oncotarget (2020)
Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model
Thorsten Heilmann et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2020)
Senolytic drugs: from discovery to translation
J. L. Kirkland et al.
JOURNAL OF INTERNAL MEDICINE (2020)
Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology
Aleksandra Zielinska et al.
MOLECULES (2020)
Targeted Delivery of Dasatinib to Deplete Tumor-Associated Macrophages by Mannosylated Mixed Micelles for Tumor Immunotherapy
Xiaoxu Zhang et al.
ACS BIOMATERIALS SCIENCE & ENGINEERING (2020)
Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia
Gabriella Mezei et al.
PLATELETS (2019)
Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
James Nyagwange et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2019)
A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer
Linda R. Duska et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Magnetically Guided Self-Assembled Protein Micelles for Enhanced Delivery of Dasatinib to Human Triple-Negative Breast Cancer Cells
Sally A. Sabra et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+Metastasic Breast Cancer
Enrique Niza et al.
NANOMATERIALS (2019)
Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia
Youssef Ghosn et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2019)
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature
Seniz Ongoren et al.
HEMATOLOGY (2018)
Experience with dasatinib and nilotinib use in pregnancy
Theodora Barkoulas et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
Patrick G. Morris et al.
CLINICAL BREAST CANCER (2018)
Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study
Shuichi Mizuta et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Comprehensive review of cardiovascular toxicity of drugs and related agents
Premysl Mladenka et al.
MEDICINAL RESEARCH REVIEWS (2018)
A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma
Jingya Sun et al.
THERANOSTICS (2018)
Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra et al.
JOURNAL OF NANOBIOTECHNOLOGY (2018)
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
Jun Tian et al.
BRITISH JOURNAL OF CANCER (2018)
Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma
Ibrahim El Sayed et al.
LIFE SCIENCES (2018)
Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia
Aya Nakaya et al.
HEMATOLOGY REPORTS (2018)
Improving Tumor Specificity and Anticancer Activity of Dasatinib by Dual-Targeted Polymeric Micelles
Qing Yao et al.
ACS APPLIED MATERIALS & INTERFACES (2017)
ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model
Rajendar K. Mittapalli et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
Dilek Keskin et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Different types of intranasal steroids for chronic rhinosinusitis
Lee Yee Chong et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Ingredients in Fruit Juices Interact with Dasatinib Through Inhibition of BCRP: A New Mechanism of Beverage-Drug Interaction
Brett Fleisher et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye
Guo Yu et al.
LANCET ONCOLOGY (2014)
Dasatinib: A Guide to Its Use in Chronic Myeloid Leukemia in the EU
Gillian M. Keating et al.
BIODRUGS (2013)
Interactions between oral antineoplastic agents and concomitant medication: a systematic review
Esther Carcelero et al.
EXPERT OPINION ON DRUG SAFETY (2013)
The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment
Nitin Jain et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study
Xiaoning Wang et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2013)
Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A
Stephen J. Blake et al.
EXPERIMENTAL HEMATOLOGY (2012)
Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
Antonio Garcia-Gomez et al.
PLOS ONE (2012)
Dasatinib A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
Paul L. McCormack et al.
DRUGS (2011)
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development
Massimo Breccia et al.
EXPERT OPINION ON DRUG SAFETY (2010)
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
T. Koreckij et al.
BRITISH JOURNAL OF CANCER (2009)
Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling
Jyoti Nautiyal et al.
CANCER LETTERS (2009)
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
Kimmo Porkka et al.
BLOOD (2008)
Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds
Elaine M. Merisko-Liversidge et al.
TOXICOLOGIC PATHOLOGY (2008)
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
Amrita V. Kamath et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Nanostructured lipid carriers (NLC) in cosmetic dermal products
R. H. Mueller et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Share Paper
